- Home
- FUTU vs PCVX Comparison
FUTU vs PCVX Comparison
Compare FUTU & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FUTU
- PCVX
- Stock Information
- Founded
- FUTU 2011
- PCVX 2013
- Country
- FUTU Hong Kong
- PCVX United States
- Employees
- FUTU N/A
- PCVX N/A
- Industry
- FUTU Investment Bankers/Brokers/Service
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- FUTU Finance
- PCVX Health Care
- Exchange
- FUTU Nasdaq
- PCVX Nasdaq
- Market Cap
- FUTU 11.6B
- PCVX 13.2B
- IPO Year
- FUTU 2019
- PCVX 2020
- Fundamental
- Price
- FUTU $87.53
- PCVX $85.30
- Analyst Decision
- FUTU Buy
- PCVX Strong Buy
- Analyst Count
- FUTU 4
- PCVX 9
- Target Price
- FUTU $85.50
- PCVX $149.38
- AVG Volume (30 Days)
- FUTU 1.6M
- PCVX 1.2M
- Earning Date
- FUTU 03-13-2025
- PCVX 02-25-2025
- Dividend Yield
- FUTU N/A
- PCVX N/A
- EPS Growth
- FUTU 2.20
- PCVX N/A
- EPS
- FUTU 4.09
- PCVX N/A
- Revenue
- FUTU $1,307,165,497.00
- PCVX N/A
- Revenue This Year
- FUTU $36.79
- PCVX N/A
- Revenue Next Year
- FUTU $17.27
- PCVX N/A
- P/E Ratio
- FUTU $21.41
- PCVX N/A
- Revenue Growth
- FUTU 11.68
- PCVX N/A
- 52 Week Low
- FUTU $43.61
- PCVX $58.10
- 52 Week High
- FUTU $130.50
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- FUTU 58.46
- PCVX 48.31
- Support Level
- FUTU $78.58
- PCVX $77.52
- Resistance Level
- FUTU $83.55
- PCVX $89.65
- Average True Range (ATR)
- FUTU 2.89
- PCVX 3.95
- MACD
- FUTU 0.73
- PCVX 0.77
- Stochastic Oscillator
- FUTU 89.84
- PCVX 62.04
About FUTU Futu Holdings Limited
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.